Shikha Saxena1, Jerica Gee2, Sarah Klieger2, Adriana Kajon3, Hans Petersen3, Theoklis Zaoutis4,5,6,2, Brian Fisher4,5,6,2. 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia. 2. Division of Infectious Diseases and Center for Pediatric Clinical Effectiveness Research, Children's Hospital of Philadelphia, Pennsylvania. 3. Lovelace Respiratory Research Institute, Albuquerque, New Mexico. 4. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia. 5. Department of Pediatrics, University of Pennsylvania, Philadelphia. 6. Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia.
Abstract
BACKGROUND: Solid organ transplant (SOT) recipients are at risk for invasive fungal disease (IFD). Data on IFD burden in pediatric patients are limited. We aimed to determine the incidence and outcome of IFD in a large cohort of pediatric patients who underwent SOT. METHODS: A single-center cohort of pediatric patients who underwent SOT between 2000 and 2013 was assembled retrospectively. The patients were followed for 180 days after transplant or until death to determine the presence or absence of IFD. The 2008 European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group criteria were used to define IFD as proven or probable. The incidence of IFD, all-cause mortality rate, and case-fatality rate at 180 days were calculated. RESULTS: Among 584 pediatric patients who underwent SOT, 13 patients sustained 14 episodes of IFD (candidiasis, aspergillosis, and mucormycosis). The overall incidence was 2.2% (14.3 IFD events per 100000 patient-days). The IFD rates according to transplant type were 12.5% (1 of 8) (heart/lung), 11.4% (4 of 35) (lung), 4.7% (8 of 172) (liver), 0% (0 of 234) (kidney), and 0% (0 of 135) (heart). Three patients with IFD (2 lung and 1 heart/lung) died, and all these deaths were deemed likely attributable to the IFD; the case-fatality rate was 21.4% (3 of 14). CONCLUSIONS: The overall incidence of IFD in these pediatric SOT recipients was low but varied across transplant type, with heart/lung and lung recipients having the highest IFD rate. Given the attributable case-fatality rate, the risk of death resulting from IFD is potentially high. More data on groups at higher risk, such as lung transplant recipients, are needed to guide targeted antifungal prophylaxis.
BACKGROUND: Solid organ transplant (SOT) recipients are at risk for invasive fungal disease (IFD). Data on IFD burden in pediatric patients are limited. We aimed to determine the incidence and outcome of IFD in a large cohort of pediatric patients who underwent SOT. METHODS: A single-center cohort of pediatric patients who underwent SOT between 2000 and 2013 was assembled retrospectively. The patients were followed for 180 days after transplant or until death to determine the presence or absence of IFD. The 2008 European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group Consensus Group criteria were used to define IFD as proven or probable. The incidence of IFD, all-cause mortality rate, and case-fatality rate at 180 days were calculated. RESULTS: Among 584 pediatric patients who underwent SOT, 13 patients sustained 14 episodes of IFD (candidiasis, aspergillosis, and mucormycosis). The overall incidence was 2.2% (14.3 IFD events per 100000 patient-days). The IFD rates according to transplant type were 12.5% (1 of 8) (heart/lung), 11.4% (4 of 35) (lung), 4.7% (8 of 172) (liver), 0% (0 of 234) (kidney), and 0% (0 of 135) (heart). Three patients with IFD (2 lung and 1 heart/lung) died, and all these deaths were deemed likely attributable to the IFD; the case-fatality rate was 21.4% (3 of 14). CONCLUSIONS: The overall incidence of IFD in these pediatric SOT recipients was low but varied across transplant type, with heart/lung and lung recipients having the highest IFD rate. Given the attributable case-fatality rate, the risk of death resulting from IFD is potentially high. More data on groups at higher risk, such as lung transplant recipients, are needed to guide targeted antifungal prophylaxis.
Authors: Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller Journal: Clin Infect Dis Date: 2010-04-15 Impact factor: 9.079
Authors: Theoklis E Zaoutis; Steven Webber; David C Naftel; Mary Anne Chrisant; Beth Kaufman; F B Pearce; Robert Spicer; Anne I Dipchand Journal: Pediatr Transplant Date: 2010-11-26
Authors: Theoklis E Zaoutis; Kateri Heydon; Jaclyn H Chu; Thomas J Walsh; William J Steinbach Journal: Pediatrics Date: 2006-03-13 Impact factor: 7.124
Authors: Lara A Danziger-Isakov; Sarah Worley; Susana Arrigain; Paul Aurora; Manfred Ballmann; Debra Boyer; Carol Conrad; Irmgard Eichler; Okan Elidemir; Samuel Goldfarb; George B Mallory; Marian G Michaels; Peter Michelson; Peter J Mogayzel; Daiva Parakininkas; Melinda Solomon; Gary Visner; Stuart Sweet; Albert Faro Journal: J Heart Lung Transplant Date: 2008-04-24 Impact factor: 10.247
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: F Pugliese; F Ruberto; A Cappannoli; S M Perrella; K Bruno; S Martelli; V Marcellino; A D'Alio; D Diso; M Rossi; S G Corradini; V Morabito; M Rolla; G Ferretti; F Venuta; P B Berloco; G F Coloni; P Pietropaoli Journal: Transplant Proc Date: 2007 Jul-Aug Impact factor: 1.066
Authors: Michael Kueht; Joshua A Villarreal; Edward Reece; N Thao N Galvan; Krupa Mysore; Alejandro Restrepo; Norma Quintanilla; Abbas Rana; John Goss Journal: Plast Reconstr Surg Glob Open Date: 2019-01-15
Authors: J T Ramos; C A Romero; S Belda; F J Candel; B Carazo Gallego; A Fernández-Polo; L Ferreras Antolín; C Garrido Colino; M L Navarro; O Nef; P Olbright; E Rincón-López; J Ruiz Contreras; P Soler-Palacín Journal: Rev Esp Quimioter Date: 2019-09-11 Impact factor: 1.553